BR9800524A - Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituìda na posição 8 - Google Patents

Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituìda na posição 8

Info

Publication number
BR9800524A
BR9800524A BR9800524-3A BR9800524A BR9800524A BR 9800524 A BR9800524 A BR 9800524A BR 9800524 A BR9800524 A BR 9800524A BR 9800524 A BR9800524 A BR 9800524A
Authority
BR
Brazil
Prior art keywords
lower alkyl
phenyl
hydrogen
triaza
decan
Prior art date
Application number
BR9800524-3A
Other languages
English (en)
Other versions
BR9800524B1 (pt
Inventor
Geo Adam
Andrea Cesura
Guido Galley
Francois Jenck
Frederick Monsma
Stephan Roever
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9800524A publication Critical patent/BR9800524A/pt
Publication of BR9800524B1 publication Critical patent/BR9800524B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Patente de Invenção:<B>"DERIVADOS DE 1,4,3-TRIAZA-ESPIRO[4,5]DE-CAN-4-ONA SUBSTITUìDA NA POSIçãO 8"<D>. A presente invenção refere-se a compostos da fórmula: onde: R^ 1^ e R^ 2^ são, independentemente um do outro, hidrogênio, alquila inferior, alcóxi inferior ou halogênio; R^ 3^ é fenila, opcionalmente substituída por alquila inferior, CF~ 3~, alcóxi inferior ou halogênio; e R^ 4^ é hidrogênio, alquila inferior, alquenila inferior, -C(O)-alquila inferior, -C(O)-fenila, alquila inferior-C(O)-fenila, alquileno inferior-C(O)O-alquila inferior, alcanotriila-di-inferior-C(O)O-alquila inferior, hidróxi-alquila inferior, alquila inferior-O-alquila inferior, alquila inferior-CH(OH)CF~ 3~, fenila ou benzila, R^ 5^ e R^ 6^ são, independentemente um do outro, hidrogênio, fenila, alquila inferior ou di-alquila inferior ou podem formar conjuntamente um anel fenila, e R^ 5^ e um de R^ 1^ ou R^ 2^ podem formar conjuntamente um anel de 6 elementos saturado ou não-saturado, A é um anel saturado de 4 a 7 elementos, que pode conter um heteroátomo, tal como O ou S, e a sais de adição de ácido farmaceuticamente aceitáveis dos mesmos que são agonistas e/ou antagonistas do receptor OFQ.
BRPI9800524-3A 1997-01-30 1998-01-30 derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituÍda na posiÇço 8, medicamento que os contÉm, processo para preparaÇço dos mesmos, bem como seu uso. BR9800524B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97101409 1997-01-30
EP97119311 1997-11-05

Publications (2)

Publication Number Publication Date
BR9800524A true BR9800524A (pt) 2000-03-14
BR9800524B1 BR9800524B1 (pt) 2008-11-18

Family

ID=26145196

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9800524-3A BR9800524B1 (pt) 1997-01-30 1998-01-30 derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituÍda na posiÇço 8, medicamento que os contÉm, processo para preparaÇço dos mesmos, bem como seu uso.

Country Status (34)

Country Link
US (1) US6071925A (pt)
EP (1) EP0856514B1 (pt)
JP (1) JP3292457B2 (pt)
KR (1) KR100274107B1 (pt)
CN (1) CN1113881C (pt)
AR (1) AR011576A1 (pt)
AT (1) ATE202105T1 (pt)
AU (1) AU730147B2 (pt)
BR (1) BR9800524B1 (pt)
CA (1) CA2226058C (pt)
CO (1) CO4920223A1 (pt)
CZ (1) CZ27398A3 (pt)
DE (1) DE69800896T2 (pt)
DK (1) DK0856514T3 (pt)
EA (1) EA001357B1 (pt)
ES (1) ES2158622T3 (pt)
GR (1) GR3036523T3 (pt)
HR (1) HRP980043B1 (pt)
HU (1) HUP9800138A3 (pt)
ID (1) ID19773A (pt)
IL (1) IL123036A (pt)
MA (1) MA26470A1 (pt)
NO (1) NO310026B1 (pt)
NZ (1) NZ329627A (pt)
PE (1) PE59999A1 (pt)
PL (1) PL324571A1 (pt)
PT (1) PT856514E (pt)
SG (1) SG71077A1 (pt)
SI (1) SI0856514T1 (pt)
TR (1) TR199800085A2 (pt)
TW (1) TW457238B (pt)
UY (1) UY24865A1 (pt)
YU (1) YU2098A (pt)
ZA (1) ZA98570B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0921125T1 (en) * 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
DE69803653T2 (de) * 1997-12-05 2002-08-29 F. Hoffmann-La Roche Ag, Basel 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
US6166209A (en) * 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
US6277991B1 (en) 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
DE69905798T2 (de) 1998-06-12 2004-02-12 F. Hoffmann-La Roche Ag Di- oder Triazaspiro[4,5]decanderivate
ES2181336T3 (es) * 1998-06-12 2003-02-16 Hoffmann La Roche Espiro(piperidin-4,1'-pirrolo(3,4-c)pirrol).
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
CO5150201A1 (es) * 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
EP0997464B1 (en) * 1998-10-23 2005-02-16 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
AU1185300A (en) * 1998-11-20 2000-06-13 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
GB9900078D0 (en) * 1999-01-05 1999-02-24 Zeneca Ltd Chemical compounds
GB9914024D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
AU1382901A (en) * 1999-11-17 2001-05-30 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
CN1242993C (zh) 2000-03-31 2006-02-22 日本新药株式会社 杂环衍生物和药物
MXPA03009239A (es) * 2001-04-10 2004-11-12 Johnson & Johnson Derivados de 1,3,8-triazapiro[4,5]decan-4-ona utiles para el tratamiento de trastornos mediados por el receptor orl-1.
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
WO2003004034A1 (en) 2001-07-02 2003-01-16 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
AU2003268512A1 (en) * 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
ZA200510329B (en) * 2003-05-23 2007-04-25 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
SA04250305B1 (ar) 2003-09-25 2008-06-02 سولفاي فارماسوتيكالز بي . في مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
CN103202840B (zh) * 2006-11-28 2015-02-11 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
CN101622241B (zh) 2007-03-01 2013-05-22 田边三菱制药株式会社 苯并咪唑化合物及其医药用途
EP2150552B1 (en) * 2007-04-09 2013-01-02 Janssen Pharmaceutica NV 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN122562777A (zh) * 2015-12-02 2026-08-14 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
CN106467476A (zh) * 2016-09-04 2017-03-01 王际菊 一种左旋胺基化合物的合成方法
CN106397225A (zh) * 2016-09-04 2017-02-15 王际菊 一种手性化合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US488082A (en) * 1892-12-13 Automatic gut-off for gas bxxenees
JPS5212171A (en) * 1975-07-17 1977-01-29 Yoshitomi Pharmaceut Ind Ltd Process for preparation of cyclohexane derivatives
US4076821A (en) * 1976-02-27 1978-02-28 Yoshitomi Pharmaceutical Industries, Ltd. 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof
US4160836A (en) * 1976-05-17 1979-07-10 Janssen Pharmaceutica N.V. Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
SU1095878A3 (ru) * 1980-10-22 1984-05-30 Жансен Фармасетика Н.В. (Фирма) Способ получени производных 1-(4-арилциклогексил)пиперидина или их фармацевтически пригодных солей или их стереоизомерных форм
US4374245A (en) * 1982-04-09 1983-02-15 Hoechst-Roussel Pharmaceuticals Inc. 8-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
JPS6012357B2 (ja) * 1984-01-23 1985-04-01 吉富製薬株式会社 脂環式誘導体
US4707484A (en) * 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
DE3718317A1 (de) * 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
US5153225A (en) * 1986-12-10 1992-10-06 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
US5039804A (en) * 1989-12-13 1991-08-13 Glaxo Inc. Preparation of substituted alkali metal piperidine-4-carboxylates
DE4135473A1 (de) * 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
DE4405178A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Substituierte 1,3,8-Triaza-spiro(4,5)-decan-4-on-Derivate als Vorstufen zur Herstellung von Pharmazeutika

Also Published As

Publication number Publication date
YU2098A (sh) 2001-03-07
GR3036523T3 (en) 2001-12-31
IL123036A0 (en) 1998-09-24
NO310026B1 (no) 2001-05-07
HUP9800138A3 (en) 1999-03-01
KR100274107B1 (ko) 2000-12-15
SI0856514T1 (en) 2001-08-31
US6071925A (en) 2000-06-06
CZ27398A3 (cs) 1998-08-12
PT856514E (pt) 2001-10-31
EP0856514B1 (en) 2001-06-13
DK0856514T3 (da) 2001-09-17
ES2158622T3 (es) 2001-09-01
HUP9800138A2 (hu) 1998-09-28
EA199800108A1 (ru) 1998-10-29
JPH10212290A (ja) 1998-08-11
KR19980070900A (ko) 1998-10-26
IL123036A (en) 2000-12-06
CA2226058C (en) 2008-01-29
ZA98570B (en) 1998-07-30
CN1113881C (zh) 2003-07-09
NO980332D0 (no) 1998-01-26
CO4920223A1 (es) 2000-05-29
DE69800896T2 (de) 2002-03-28
BR9800524B1 (pt) 2008-11-18
NZ329627A (en) 1999-11-29
MA26470A1 (fr) 2004-12-20
HU9800138D0 (en) 1998-03-30
CA2226058A1 (en) 1998-07-30
EA001357B1 (ru) 2001-02-26
JP3292457B2 (ja) 2002-06-17
HRP980043A2 (en) 1998-12-31
NO980332L (no) 1998-07-31
TR199800085A3 (tr) 1998-08-21
PL324571A1 (en) 1998-08-03
AU730147B2 (en) 2001-03-01
PE59999A1 (es) 1999-07-01
HRP980043B1 (en) 2001-12-31
SG71077A1 (en) 2000-03-21
TR199800085A2 (xx) 1998-08-21
AR011576A1 (es) 2000-08-30
ID19773A (id) 1998-07-30
CN1191862A (zh) 1998-09-02
TW457238B (en) 2001-10-01
ATE202105T1 (de) 2001-06-15
AU5280998A (en) 1998-08-06
EP0856514A1 (en) 1998-08-05
DE69800896D1 (de) 2001-07-19
UY24865A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
BR0209939A (pt) Composto ou seu sal, éster ou prodroga farmaceuticamente aceitável, formulação farmacêutica, uso do composto ou de seu sal, éster ou prodroga farmaceuticamente aceitável, e, método para tratar câncer
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
ES2182852T3 (es) Derivados de prolinamida.
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
YU2098A (sh) Derivati 8-supstituisanog-1,3,8-triaza-spiro/4,5/dekan-4- ona
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR9910144A (pt) Antagonistas de receptores de quimiocinas e seu uso
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
BR0308592A (pt) Derivados de piperidina ou 8-azabiciclo [3.2.1] oct-3-il-piperidina, de utilidade como moduladores da atividade do receptor de quimocina (especialmente ccr5)
IT1255802B (it) Derivati imidazolici ad attivita&#39; a ii antagonista
SE0102055D0 (sv) New Compounds
TR200000349T2 (tr) Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı.
SE0002476D0 (sv) New compounds
ES2091126T3 (es) Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
DK136987D0 (da) Selektive alfa-adrenerge receptorantagonister, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende disse
BRPI0515897A (pt) composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
SE0102057D0 (sv) New Salts I
NO883468D0 (no) Fremgangsmaate til fremstilling av farmasoeytiske blandinger inneholdende cyklopeptider som reserpsjonsbefordrere ved applikasjon paa slimhuden.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/11/2008, OBSERVADAS AS CONDICOES LEGAIS.

B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 15A ANUIDADE(S), CONFORME ART. 87 DA LPI 9.279.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.